CGTLive’s Weekly Rewind – December 1, 2023


Review top news and interview highlights from the week ending December 1, 2023.

CGTLive’s Weekly Rewind – December 1, 2023

CGTLive’s Weekly Rewind – December 1, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. FDA to Investigate Risk of T-Cell Malignancy After CAR T-Cell Therapy

The FDA has received reports of multiple T-cell malignancies in patients after approved CAR-T treatment.

2. Marcela Maus, MD, PhD, on New Approaches to CAR T-Cell Therapy for Solid Tumors

The Associate Professor of Medicine at Harvard Medical School discussed upcoming research and strategies to combat present hurdles in the treatment field.

3. Second Gene Therapy for Epidermolysis Bullosa up for Priority Review

Pz-cel has a PDUFA date of May 25, 2024.

4. Fernanda Mesquita, PhD, on Using LAMA2-Exosomes to Improve Cardiomyocyte Survival in Stroke

The research associate at the The Texas Heart Institute discussed preclinical research she presented at AHA’s 2023 Scientific Sessions on MSC-derived exosomes.

5. Autolus Submits Obe-Cel BLA for Adult R/R B-ALL

The company also plans to submit an MAA to the EMA in the first half of 2024.

Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
Manali Kamdar, MD, on Liso-Cel's Continued Efficacy in Second-Line LBCL at 3-Year Follow-up
Omid Hamid, MD, on Clinic Experience With TIL vs CAR-T Therapy Administration
N. Nora Bennani, MD, on Diving Deeper Into T-Cell Lymphomas
© 2024 MJH Life Sciences

All rights reserved.